Anika announces changes in senior management responsibilities as focus shifts to product commercialization.WOBURN, Mass.--(BUSINESS WIRE)--Jan. 30, 1996--Anika Research Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ANIK ANIK Canadian COMSAT ) announced today that Robert "Duffy" S. DuFresne, who was recently promoted to president, will now have responsibility for all operations and business development of Anika. David A. Swann, Ph.D., formerly chief executive officer, will continue as chairman of the board as well as holding the newly created position of chief scientific officer. "Anika is evolving from the research phase to product commercialization," said Dr. David A. Swann, chairman and chief scientific officer of Anika. "Duffy has the experience and drive to build Anika's position in the emerging market for hyaluronic acid hyaluronic acid: see mucopolysaccharide. Hyaluronic acid A polysaccharide which is an integral part of the gel-like substance of animal connective tissue; it supposedly serves as a lubricant and shock absorbent in the joints. in the treatment of osteoarthritis osteoarthritis or osteoarthrosis or degenerative joint disease Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first. ." Duffy S. DuFresne, president of Anika, stated, "Dr. Swann will now be able to focus his scientific expertise on Anika's exciting research and product development programs as well as providing technical guidance regarding the manufacturing of hyaluronic acid based products." Anika Research Inc. is dedicated to the development and manufacturing of technologically advanced hyaluronic acid products for surgical and therapeutic medical applications. Product development programs include: ORTHOVISC, Anika's lead compound for the treatment of osteoarthritis and temporomandibular joint (TMJ TMJ abbr. temporomandibular joint syndrome Temporomandibular joint pain (TMJ) Pain and other symptoms affecting the head, jaw, and face that are caused when the jaw joints and muscles controlling them don't work ) dysfunction; INCERT for the prevention of surgical adhesions; and HA oligosaccharides oligosaccharides (ol´igōsak´  rīdz),n. for the treatment of cancer. CONTACT: Anika Research Inc. Sean Moran, 617/932-6616 or Feinstein Partners Doug MacDougall, 617/577-8110 |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion